An Additional Dose Of Viral Vector Covid-19 Vaccine And Mrna Covid-19 Vaccine In Kidney Transplant Recipients: A Randomized Controlled Trial
1Division of Infectious Diseases, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, 2Immunology Laboratory, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, 3Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, 4Office of Research, Academic Affairs and Innovation, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, 5Division of Nephrology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
Meeting: 2022 American Transplant Congress
Abstract number: 9065
Keywords: COVID-19, Immunogenicity, Immunosuppression, Kidney transplantation
Topic: Basic & Clinical Science » Basic & Clinical Science » 73 - COVID-19
Session Information
Session Time: 7:00pm-8:00pm
Presentation Time: 7:00pm-8:00pm
Location: Hynes Halls C & D
*Purpose: An additional dose of the COVID-19 vaccine following a primary series is recommended for solid organ transplant recipients. However, a comparison of the immunogenicity and safety of an additional dose of COVID-19 vaccine among different platforms has not been investigated.
*Methods: Eligible adult KT recipients were randomized using a stratified (by a previous vaccine regimen) block randomization approach to receive either ChAdOx1 nCoV-19 vaccine (AstraZeneca); V group, or mRNA vaccine (Pfizer-BioNTech or mRNA-1273); M group. Two weeks later, humoral immunity (HMI) was evaluated by anti-RBD IgG level, and percentages of neutralizing antibody inhibition using surrogate viral neutralization test (%SVNT), and cell-mediated immunity (CMI) was investigated by the ELISpot assays.
*Results: A total of 85 KT recipients were included. Of those, 62% were male with the median (IQR) age of 50 (43-59) years. The median (IQR) duration after transplantation was 46 (26-82) months. Twenty-six (34%) and 51 (66%) of those received two-dose of CoronaVac followed by one dose of ChAdOx1 nCoV-19 vaccine and two-dose of ChAdOx1 nCoV-19 vaccine, respectively. Of all, 42 and 43 patients were assigned to V and M groups, respectively. At two weeks after an additional dose, KT recipients in the M group elicited a greater trend of the median (IQR) anti-RBD antibody levels compared to those in the V group (51.8 [5.1-591] vs. 28.5 [2.9-119.3] BAU/mL,p=0.18), which resulted in significantly higher seroconversion rate (anti-RBD antibody > 7.1 BAU/mL) in M group than those in V group (83%vs.51%, p<0.01). Additionally, sVNT positivity rate (%SVNT > 35%) were also significantly greater in M group (58%vs32%, p=0.03). However, there was no difference in S1-specific T cell and RBD-specific B cell responses between M and V groups (230 [41-420] vs. 268 [118-510] SFUs/106 PMBCs, p=0.65 and 2 [0-10] vs. 2 [0-13] SFUs/106 PMBCs, p=0.60). Adverse events were mild and similar between groups (p=NS).
*Conclusions: KT recipients who received an additional dose of mRNA COVID-19 vaccine could elicit HMI greater than a viral vector COVID-19 vaccine along with comparable CMI and safety profile. (TCTR20211102003).
To cite this abstract in AMA style:
Bruminhent J, Setthaudom C, Phornkittikorn P, Chaumdee P, Prasongtanakij S, Srisala S, Malathum K, Boongird S, Nongnuch A, Assanatham M, Kiertiburanakul S. An Additional Dose Of Viral Vector Covid-19 Vaccine And Mrna Covid-19 Vaccine In Kidney Transplant Recipients: A Randomized Controlled Trial [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/an-additional-dose-of-viral-vector-covid-19-vaccine-and-mrna-covid-19-vaccine-in-kidney-transplant-recipients-a-randomized-controlled-trial/. Accessed May 30, 2025.« Back to 2022 American Transplant Congress